Edition:
United Kingdom

People: Alkermes Plc (ALKS.OQ)

ALKS.OQ on NASDAQ Stock Exchange Global Select Market

21.48USD
18 Sep 2019
Change (% chg)

$0.05 (+0.23%)
Prev Close
$21.43
Open
$21.36
Day's High
$21.72
Day's Low
$21.03
Volume
315,085
Avg. Vol
530,687
52-wk High
$45.12
52-wk Low
$19.37

Cooke, Shane 

Mr. Shane M. Cooke is Director of the Company. Mr. Cooke served as President of the Company and of Alkermes Pharma Ireland Limited (“APIL”), a wholly-owned subsidiary of the Company, from September 2011 until his retirement in March 2018. He became a director of the Company upon his retirement. Mr. Cooke has been Chairman of the Board of APIL since September 2011. From May 2007 to September 16, 2011, Mr. Cooke was Executive Vice President of Elan Corporation, plc (“Elan”) and Head of Elan Drug Technologies. Mr. Cooke served as the Chief Financial Officer of Elan from July 2001, when he joined Elan, until May 2011. From May 2005 to September 16, 2011, Mr. Cooke served as a director of Elan. Prior to joining Elan, Mr. Cooke was Chief Executive of Pembroke Capital Limited, an aviation leasing company, and prior to that, held a number of senior positions in finance in the banking and aviation industries. He is a chartered accountant. He is currently on the board of directors of Prothena Biosciences and Prothena Therapeutics, both subsidiaries of publicly traded Prothena Corporation plc, as well as Endo International plc, a publicly traded company.

Basic Compensation

Total Annual Compensation, USD 605,134
Restricted Stock Award, USD 982,260
Long-Term Incentive Plans, USD --
All Other, USD 2,884,070
Fiscal Year Total, USD 4,471,460

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 60,000 2,678,040.00
Name Fiscal Year Total

Richard Pops

9,380,490

James Frates

2,828,540

Elliot Ehrich

3,547,020

Iain Brown

--

David Gaffin

--

Michael Landine

--
As Of  31 Dec 2017